SESYNACT Stock Latest News
Company AnnouncementsSynAct Pharma seals first resomelagon dengue partnership in Brazil5d ago
Company AnnouncementsSynAct Pharma Launches Global Investor and Partnering Push1M ago
Company AnnouncementsWHO Endorses SynAct Pharma’s Resomelagon as Key Dengue Drug Candidate1M ago- Company AnnouncementsSynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals1M ago
Company AnnouncementsSynAct Pharma Executives Sell Shares to Cover Danish Tax Liabilities1M ago
Company AnnouncementsSynAct Pharma Expands Resomelagon’s Potential With New Preclinical Inflammation Data2M agoCompany AnnouncementsSynAct Pharma Details 2026 First-Half Progress in Inflammatory Disease R&D2M ago
Company AnnouncementsSynAct Pharma strikes first resomelagon commercial deal in Brazil’s dengue market2M ago
Company AnnouncementsSynAct Pharma Wins Key US Patent Ruling on Resomelagon Tablet Formulation2M ago
Company AnnouncementsSynAct Pharma Secures New Financing Facility to Bolster Phase III Readiness3M ago
Company AnnouncementsSynAct preclinical data point to osteoarthritis potential for resomelagon3M ago- Company AnnouncementsSynAct Pharma draws heightened partner interest as ADVANCE data boost resomelagon’s strategic appeal4M ago
Company AnnouncementsSynAct Pharma Leadership Locks Up Shares Through 2026 to Signal Long-Term Confidence4M agoCompany AnnouncementsSynAct’s RA Drug Resomelagon Delivers Positive Phase 2b Data, Fuels Partnering Push4M ago
Company AnnouncementsSynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 20444M ago
Company AnnouncementsSynAct Pharma AGM Confirms No Dividend and Renews Mandate for New Share Issues4M ago
Company AnnouncementsSynAct Pharma Details Q1 2026 Progress in Inflammation-Focused Biotech Strategy5M ago
Company AnnouncementsSynAct Pharma Clarifies Large Shareholder’s Erroneous Share Sale Order5M ago
Company AnnouncementsSynAct Pharma to Showcase Lead Inflammation Drug Ahead of Key Rheumatoid Arthritis Data5M ago
Company AnnouncementsSynAct Pharma convenes AGM and opts to retain earnings5M ago